What was filed
Aurobindo Pharma told the exchanges that its wholly owned US subsidiary, Aurobindo Pharma USA Inc. (APUSA), has completed its acquisition of Lannett Company, Inc. from Lannett Seller Holdco, Inc. The deal closed effective June 29, 2026, following approval from the U.S. Federal Trade Commission on June 18, 2026. Lannett will now operate as Lannett Company LLC, a wholly owned subsidiary of APUSA.
The filing follows Aurobindo's earlier letter of June 19, 2026 and a press release of June 22, 2026 relating to the same transaction.
What comes with the deal
Per the filing, integration will begin immediately, with the company stating an emphasis on uninterrupted access to critical medications, continuity of partner relationships, and support for employees through the transition. Aurobindo said APUSA welcomes the incoming Lannett workforce, adding to its US talent base and operational capabilities.
The filing does not disclose the purchase price, financing terms, or any financial metrics of the acquired business.
Why it matters to a holder
This filing confirms that a previously announced acquisition has now legally closed — the regulatory condition (FTC approval) has been cleared and Lannett is now a subsidiary. For a holder, the disclosure marks the shift from a pending transaction to one where integration and consolidation of the US business begin. The filing itself carries no numbers on deal size or expected impact, so the operational and financial effect is not quantified here.